View this email in your browser

Pfizer are pleased to have supported ESCMID Global 2024. We hope you enjoyed the conference.

Here is a recap of the valuable insights from Pfizer Anti-Infectives, where esteemed physicians and infectious disease specialists shared expertise at our sponsored symposia and Innovation Theatre sessions.
The Global Threat of AMR: Understanding the Challenge and Advancing Solutions

Antimicrobials are a critical backbone of modern medicine, yet there is a concerning rise in resistance to these medicines.¹ This fireside chat with Dr Jay Purdy (Anti-Bacterials & Anti-Fungals Lead, Medical Affairs) and Jennifer Young Maloney (Vice President, Specialty Care Global Policy & Public Affairs) discusses the challenges driving antimicrobial resistance (AMR) and the urgent need for us to collaborate on solutions to help combat AMR and ensure a future with effective antimicrobials. Because Time is Life.
Watch now
The clock is ticking – crucial first steps towards early appropriate treatment of MDR Gram-negative bacterial infections

‘Time waits for no one’. This is especially true when managing patients with difficult-to-treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria.¹ The plethora of evidence and perspectives to support effective management of these infections is rapidly evolving, however, there is one constant - acting early with appropriate treatment impacts patient outcomes.² Knowing what treatment strategy to adopt continues to challenge clinicians³ and this integrated session sets out to consider the optimal approach. Led by Prof. David van Duin (Pfizer-appointed) and Prof. Spyros Pournaras (ESCMID-appointed), our multidisciplinary faculty will share tips on how to promptly identify patients at risk of MDR Gram-negative bacterial infection, highlight the pivotal role of the microbiologist in supporting early identification and diagnosis, and discuss how to select the most appropriate treatment for the patient in front of them.
Watch now
Challenge Accepted: Innovating AMR Surveillance through Data

Hear Dr. Katherine Perez (Senior Director, Infectious Diseases Surveillance and RWE Lead) share details on the ATLAS surveillance programme and the value of the data. Dr. Perez discusses how artificial intelligence can help crack the code on MDR infections, enabling more patients to receive early and appropriate treatment.
Watch now
How can data prepare us for the rising threat of the MBL-producing Enterobacterales or the management of CAP and cSSTI?

With antimicrobial resistance continuing to threaten many of the gains of modern medicine, tapping into available data remains essential in combatting this global public health challenge.⁴ Listen to an international expert panel, led by Dr. Alex Soriano (Pfizer-appointed) and Prof. Yehuda Carmeli (ESCMID-appointed), as they examine the evolving epidemiology of MBL-producing Enterobacterales, their anticipated burden on healthcare systems and why early identification and diagnosis of at-risk patients should be done with the utmost urgency. Discussions will also consider the clinical data and real-world evidence that have helped optimise treatment regimens for Gram-positive bacterial infections and led to a reduction in healthcare resource utilisation.
Watch now
We hope there's lots you can learn from these recordings. Thank you for making ESCMID Global 2024 a great success, we look forward to seeing you in Vienna in 2025!
Abbreviations
AMR, antimicrobial resistance; CAP, community-acquired pneumonia; cSSTIs, complicated skin and soft tissue infections; MDR, multidrug-resistant; MBL, metallo-β-lactamases; RWE, real world evidence.
 
References 
1. Bonine NG, et al. Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. Am J Med Sci. 2019 Feb;357(2):103-110; 2. Satlin MJ, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clin Infect Dis. 2022 Dec;75(12):2066–2075; 3. Paul M, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022 Apr;28(4):521–547. 4. World Health Organization. Antimicrobial Resistance. 2023. Available at: www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed April 2024)

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.